Lecigon
Asset
Continuous intestinal delivery of levodopa, carbidopa, and entacapone to manage motor fluctuations.
- Stage
- Human trials
- Modality
- Small molecule
- Target
- Ddc
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Advanced Parkinson disease
Human trials, Active not recruiting, NCT05043103, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors2
Every asset’s record: target, stage, trials and the evidence behind it.